Evidence map›Paper›PMID 33313147›Full record

ArticleAnnals of translational medicine2020

The role of associating liver partition and portal vein ligation for staged hepatectomy in unresectable hepatitis B virus-related hepatocellular carcinoma.

Lixin Ke, Rui Shen, Wenzhe Fan, Wenjie Hu, Shunli Shen, Shaoqiang Li, Ming Kuang, Lijian Liang, Jiaping Li, Baogang Peng and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Lixin KeDepartment of Liver Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Rui ShenDepartment of Liver Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Wenzhe FanDepartment of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Wenjie HuDepartment of Liver Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Shunli ShenDepartment of Liver Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Shaoqiang LiDepartment of Liver Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Ming KuangDepartment of Liver Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Lijian LiangDepartment of Liver Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Jiaping LiDepartment of Interventional Oncology, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Baogang PengDepartment of Liver Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Yunpeng HuaDepartment of Liver Surgery, the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
The First Affiliated Hospital, Sun Yat-sen University · CNSun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) for hepatocellular carcinoma (HCC) remains controversial.

methodsThe records of 23 consecutive patients with hepatitis B virus (HBV)-related HCC who underwent ALPPS at our center between November 2013 and June 2018 were retrospectively reviewed. Oncological results were compared between patients who received ALPPS and those that received transarterial chemoembolization (TACE) using propensity score matching (PSM) analysis.

resultsIn patients with a single tumor (n=12) the median tumor diameter was 13.0 (range: 5.1-20.0) cm, whereas in patients with multiple tumors (n=11) the median total tumor diameter was 6.3 (range: 2.3-26.0) cm. After the stage-1 ALPPS, the median future liver remnant (FLR) increased by 50.0%. The stage-2 ALPPS was completed in 20 patients (87.0%) after a median of 12 days. The 90-day mortality rate was 13% (3/23). The overall survival (OS) rates at 1-, 2-, and 5-year were 61.1%, 34.9%, and 8.7%, respectively, whereas the disease-free survival (DFS) rates at 1-, 2-, and 5-year were 27.8%, 27.8%, and 0.0%, respectively. PSM analysis showed no difference in OS between patients who underwent ALPPS and those that received TACE [P=0.178, Barcelona Clinic Liver Cancer (BCLC) stage A-C patients; P=0.241, BCLC stage B and C patients].

conclusionsALPPS is a safe and effective treatment option for unresectable HBV-related HCC. However, for HBV-related intermediate and advanced HCC patients, ALPPS may not be superior to TACE.

Indexed as

Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS)hepatocellular carcinoma (HCC)propensity score matching (PSM)transarterial chemoembolization (TACE)

Identifiers

PMID33313147
PMCPMC7723523
OpenAlexW3092195018

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.